GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Third Harmonic Bio Inc (NAS:THRD) » Definitions » Ending Cash Position

THRD (Third Harmonic Bio) Ending Cash Position : $285.52 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Third Harmonic Bio Ending Cash Position?

Third Harmonic Bio's Ending Cash Position for the quarter that ended in Dec. 2024 was $285.52 Mil.

Third Harmonic Bio's quarterly Ending Cash Position increased from Jun. 2024 ($255.78 Mil) to Sep. 2024 ($296.55 Mil) but then declined from Sep. 2024 ($296.55 Mil) to Dec. 2024 ($285.52 Mil).

Third Harmonic Bio's annual Ending Cash Position declined from Dec. 2022 ($289.32 Mil) to Dec. 2023 ($269.52 Mil) but then increased from Dec. 2023 ($269.52 Mil) to Dec. 2024 ($285.52 Mil).

Third Harmonic Bio Ending Cash Position Historical Data

The historical data trend for Third Harmonic Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Third Harmonic Bio Ending Cash Position Chart

Third Harmonic Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
8.28 128.28 289.32 269.52 285.52

Third Harmonic Bio Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 269.52 263.28 255.78 296.55 285.52

Third Harmonic Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Third Harmonic Bio's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=269.523+15.993
=285.52

Third Harmonic Bio's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=296.536+-11.02
=285.52

Third Harmonic Bio Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Third Harmonic Bio's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Third Harmonic Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Third Harmonic Bio Inc (NAS:THRD) » Definitions » Ending Cash Position
Comparable Companies
ALMS CADL CDTX HUMA PLX PRME FHTX DSGN NGNE SLRN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
1700 Montgomery Street, Suite 210, San Francisco, CA, USA, 94111
Website
https://www.thirdharmonicbio.com
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
Executives
Edward R. Conner officer: Chief Medical Officer 501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Julie Person officer: Chief Administrative Officer C/O THIRD HARMONIC BIO, INC., 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Natalie C. Holles director, officer: CEO C/O HYPERION THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE CA 94005
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022